Veradermics completed enrolment for both Phase III VDPHL01 trials in male pattern hair loss, totalling over 1,000 participants.

Feb 9, 2026 · Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company focused on turning everyday dermatology and aesthetics problems into clear, proven care.

under development for treatment of hair loss. It is being developed by Veradermics under the developmental code name VDPHL01. As of September 2025, it is

Veradermics has finished enrollment in its second pivotal Phase 3 trial of VDPHL01, results expected for 1H 2026!!!! source: [https://ir.veradermics.com/news-releases/news-release-details/veradermics...

Veradermics is advancing a focused pipeline of product candidates designed to address high-value dermatologic conditions with limited proven solutions, combining proven mechanisms with innovative …

nSpeed. In our proprietary market surveys of Americans with PHL, survey respondents cited more rapid onset of growth as a primary desire in a treatment for PHL. In our Phase 2 open-label trial, the ma...

Feb 9, 2026 · Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company focused on turning everyday dermatology and aesthetics problems into clear, proven care.

This is the press release of the clinical trial phase 2. They have finished to enroll for the phase 3. Seems good news. [https://www.veradermics.com/veradermics-completes-phase2-3-enrollment/](https:/...

Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company focused on turning everyday dermatology and aesthetics problems into clear, proven care.

Here’s a link to a business post made a couple of days ago. https://www.bloomberg.com/news/articles/2026-02-04/hair-loss-firm-veradermics-jumps-124-after-256-million-ipo As of now it’s market c...

Oct 16, 2025 · Veradermics’ lead program, VDPHL01, is an extended-release oral minoxidil tablet in Phase 3 development for the treatment of pattern hair loss — the largest aesthetics condition �...

I just completed the 1 year long trial, and wanted to share my results. (You can find fairly extensive previous Q&A in my post history.) Some details: M, early 50’s, been experiencing slowly inc...

Veradermics aims to change this. We’re a new style of pharmaceutical company: driven by purpose, powered by science, and committed to bold therapeutic progress. Our differentiated pipeline is …

https://www.tradingview.com/news/tradingview:d8ac31a40cbda:0-veradermics-dermatology-biopharma-focused-on-hair-loss-files-for-nyse-ipo/...

Dec 11, 2024 · NEW HAVEN, Conn.– (BUSINESS WIRE)–Veradermics, a late clinical-stage aesthetics and dermatology-focused biopharmaceutical company developing first-in-class therapeutics for …

Male. Early 50’s. ~25 years of progressive hair loss. I’m taking the medication 2x/day as part of a clinical trial, and I’m satisfied with the progress so far. ...

Feb 4, 2026 · Veradermics is on a mission to make long-ignored dermatology and aesthetics conditions simple — replacing false hope, confusion, and questionable results with solutions that people a...

Source: [https://www.barrons.com/articles/veradermics-ipo-stock-price-bf5ed7e8](https://www.barrons.com/articles/veradermics-ipo-stock-price-bf5ed7e8)...

Meet our team, who bring front-line clinical experience and a passionate drive to the forefront of dermatological healthcare. Learn more.

$MANE - Veradermics - (IPO: INITIAL PUBLIC OFFERING) - DRUG: VDPHL01 READ THE PROSPECTUS: https://www.sec.gov/Archives/edgar/data/1827635/000162828026003764/veradermicsincs-1a.htm Congrats, you're a...

Dec 11, 2025 · Veradermics’ lead program, VDPHL01, is an extended-release oral minoxidil tablet in Phase 3 development for the treatment of pattern hair loss — the largest aesthetics condition �...

.5mg dut, foam x2 a day , 3x a week dermastamp...